P1-084: Mammalian target of rapamycin (mTOR) inhibition by RAD001 in patients (pts) with reccurent non-small cell lung cancer (NSCLC): Use of 18F fluorodeoxyglucose positron-emission tomography (FDG-PET) in evaluation of the pharmacodynamic effect  by Nogova, Lucia et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S583
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
up-staged and 2 cases (5%) were down-staged. In patients with staging 
discrepancy, PET-staging was accurate in 8 cases including undetected 
M1 disease, and conventional staging was accurate in 3 cases, based 
on overdiagnosis of N factor by PET. Synchronous malignant diseases 
(laryngeal cancer and malignant lymphoma) were detected by PET. 
One bronchioloalveolar carcinoma showing focal ground-glass opacity 
on CT was PET negative. PET correctly identiﬁed surgical candidates 
in 13 of 42 cases. In resected cases, one false negative (6%) and 3 false 
positive (19%) lymph node metastases were diagnosed by PET. Since 
the false negative case was microscopic N2 limited to one station, 
curative operation was performed. If we considered PET cN3 disease 
as a surgical contraindication, one surgical candidate would have been 
denied surgery. Maximum standardized uptake value (maxSUV) of 
all primary lesions ranged from 0 to 23.0 (8.1±4.3, mean±SD). The 
maxSUV among surgical cases (6.3±3.5) was smaller than among 
nonsurgical cases (9.3±4.4, p<0.05). The maxSUV was similar among 
the different histologic types.
Conclusions: FDG-PET/CT is useful for determining the clinical stage 
and resectability of primary lung cancer. However, false positive ﬁnd-
ings in regional lymph nodes, possibly due to past infectious diseases, 
are of major concern to be solved. A negative PET study in lymph 
nodes and distant metastases suggests that these patients can proceed 
directly to thoracotomy without mediastinoscopy. The maxSUV was 
related with resectability of primary lung cancer.
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Background: RAD001 (everolimus) is a novel inhibitor of mTOR for-
mulated for oral administration, currently investigated as an anticancer 
agent in clinical studies. In preclinical experiments a prominent impact 
of mTOR inhibition on glucose homeostasis was described with the 
transcription factor HIF-1 as one of the primary mediators of RAD001-
induced inhibition of mTOR. Moreover, the inhibition of FDG uptake 
has been demonstrated by FDG-PET imaging in preclinical models 
treated with RAD001. Therefore we reasoned that glucose metabolism 
as measured by FDG-PET might thus serve as a pharmacodynamic 
marker of RAD001 acting on its target in cancer pts. Here we report for 
the ﬁrst time on the use of FDG-PET in evaluation of the pharmacody-
namic effects of RAD001 in pts with recurrent NSCLC.
Patients and Methods: Patients with advanced NSCLC previously 
treated with either chemotherapy only or with chemotherapy and an 
EGFR inhibitor were treated with 10 mg continuous daily dose of 
RAD001 in an open label, multi-centre phase II study. A subgroup of 8 
pts enrolled in 2 of the study centres was evaluated by serial FDG-PET 
scans. FDG-PET was performed at the baseline and on the day 8 of 
treatment in all 8 patients. In addition, in 5 out of these 8 pts FDG-PET 
was performed on the day 28 of treatment. Evaluation of FDG-PET 
scans was performed centrally. The sum of the maximum standardized 
uptake values (sSUVmax) measured in up to 5 lesions was calculated at 
each time point. Percentage change of sSUVmax values from base-
line was calculated on days 8 and 28. In addition, standard computed 
tomography (CT) scans obtained at baseline (8 pts) and on day 28 (6 
pts) were evaluated and the change of the sum of the longest diameter 
of lesions (up to 10 selected lesions including those evaluated by FDG-
PET) was calculated. A lesion by lesion analysis will be presented. 
Results: Reduction of sSUVmax on day 8 was observed in all pts and 
ranged between 1.4% and 89.1%. Reduction of sSUVmax on day 28 
was less pronounced compared to the reduction on day 8.
Changes in sSUVmax (day 8 and day 28) and changes in sums of 
longest diameter of lesions evaluated by CT scans are provided in table 
below.








0701-0002 -19.4 1.5 3.3
0701-0003 -1.4 NA NA
0701-0004 -89.1 -82.3 -26.6
0701-0005 -19.2 NA NA
0601-0001 -52.2 -9.7 77.9
0601-0003 -17.4 NA 12.7
0601-0007 -13.0 -2.9 11.1
0601-0009 -20.6 -12.7 -16.7
NA=Not Available Measurements       
Conclusions: Results of this study suggest the value of FDG-PET as 
a tool for early evaluation of the pharmacodynamic effect of mTOR 
inhibitors such as RAD001 in patients with NSCLC. In addition, con-
ﬁrmation of similar results obtained in preclinical models suggests the 
usefulness of FDG-PET in clinical proﬁling of mTOR inhibitors.
Correlation of early pharmacodynamic changes evaluated by FDG-PET 
with clinical effects of RAD001 treatment should be evaluated in larger 
studies.
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Background: CT-guided Transthoracic Needle Aspiration Biopsy 
(TNAB) is widely used as a diagnostic tool in the diagnostic work-
up of thoracic lesions. The reported sensitivity for detection of lung 
neoplastic lesions with CT-guided TNB varies from 68% to 93% with 
